
Quarterly report 2025-Q3
added 11-10-2025
Editas Medicine Net Debt 2011-2026 | EDIT
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Editas Medicine
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -64.5 M | -87.1 M | -97.6 M | -181 M | - | -209 M | -102 M | -106 M | -140 M | 56.7 M | -10.2 M | 99 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 56.7 M | -209 M | -85.5 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Apellis Pharmaceuticals
APLS
|
-311 M | $ 20.7 | -1.24 % | $ 2.61 B | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.84 | 7.59 % | $ 4.58 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Axsome Therapeutics
AXSM
|
-205 M | $ 166.38 | 1.52 % | $ 8.28 B | ||
|
AbCellera Biologics
ABCL
|
14.7 M | $ 3.82 | 5.82 % | $ 1.14 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 8.73 | 3.44 % | $ 1.37 B | ||
|
Capricor Therapeutics
CAPR
|
-12.5 M | $ 26.86 | -3.83 % | $ 719 M | ||
|
Codexis
CDXS
|
12.5 M | $ 1.02 | 0.99 % | $ 74.9 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Cellectis S.A.
CLLS
|
-206 M | $ 3.8 | -2.06 % | $ 116 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
CNS Pharmaceuticals
CNSP
|
-13.6 M | $ 3.13 | -0.95 % | $ 1.2 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Collegium Pharmaceutical
COLL
|
-226 M | $ 41.6 | -0.17 % | $ 1.32 B | ||
|
Corcept Therapeutics Incorporated
CORT
|
-114 M | $ 35.97 | 0.76 % | $ 3.74 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
-706 M | $ 23.88 | 3.47 % | $ 2.92 B | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
263 K | $ 8.35 | -2.57 % | $ 36.1 M | ||
|
Curis
CRIS
|
-17 M | $ 1.08 | -5.26 % | $ 6.81 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
-53 M | $ 40.68 | -1.02 % | $ 3.83 B | ||
|
Corvus Pharmaceuticals
CRVS
|
-10.6 M | $ 17.89 | -2.03 % | $ 859 M | ||
|
Champions Oncology
CSBR
|
-8.23 M | $ 6.07 | 2.71 % | $ 82.9 M | ||
|
Citius Pharmaceuticals
CTXR
|
-2.99 M | $ 0.72 | -2.3 % | $ 4.84 M | ||
|
CEL-SCI Corporation
CVM
|
3.45 M | $ 3.83 | -10.09 % | $ 244 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
Daré Bioscience
DARE
|
-14.4 M | $ 1.61 | -5.29 % | $ 13.7 M | ||
|
DBV Technologies S.A.
DBVT
|
-25.5 M | $ 23.25 | 10.77 % | $ 2.26 B | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
Precision BioSciences
DTIL
|
-108 M | $ 4.33 | 3.1 % | $ 16.6 M | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
-60.8 M | $ 3.34 | 0.3 % | $ 1.2 M | ||
|
Dyadic International
DYAI
|
-6.38 M | $ 0.77 | -1.68 % | $ 22.2 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Edesa Biotech
EDSA
|
-7.74 M | $ 2.28 | 3.64 % | $ 7.29 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Agios Pharmaceuticals
AGIO
|
-48.9 M | $ 29.2 | -3.41 % | $ 1.69 B | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Equillium
EQ
|
-22.4 M | $ 1.92 | 5.49 % | $ 66.7 M |